Can AI Move Beyond Surface-Level Insights: Part Two

In Part Two of the Few & Far Between podcast conversation with Yochi Slonim, Co-Founder and CEO of Anima Biotech, we explore how AI is evolving from generating ideas anyone can access to building disease models that leverage proprietary data. This episode unpacks what makes smarter large language models different, why reducing hallucinations matters, and how connecting AI with the right kind of missing information could unlock entirely new possibilities in drug discovery. Slonim also explains why you can’t “beat” AI’s evolution—only work with it—and why the future of clinical research may depend on treating AI as a true collaborator with biology.

Tune in for a forward-looking discussion on where AI is heading and how it’s reshaping the way we study and treat disease.